| 非小细胞肺癌抗血管生成药物治疗进展 |
| |
| 引用本文： | 李凯. 抗血管生成治疗之路的瓶颈 对策与方向[J]. 中国肿瘤临床, 2020, 47(22): 1140-1144. DOI: 10.3969/j.issn.1000-8179.2020.22.047 |
| |
| 作者姓名： | 李凯 |
| |
| 作者单位： | 天津医科大学肿瘤医院肺部肿瘤内科, 国家肿瘤临床研究中心, 天津市肿瘤防治重点实验室, 天津市恶性肿瘤临床医学研究中心(天津市 300060) |
| |
| 摘 要： | 经历了20余年的发展，抗血管生成治疗已经成为恶性肿瘤的重要治疗手段之一，其与化疗、放疗、表皮生长因子受体（epidermal growth factor receptor，EGFR）酪氨酸激酶抑制剂以及免疫药物联合均取得了公认的疗效。但肿瘤微环境治疗药物的特性也使其面临着特有的“瓶颈”：如何有效克服其耐药、早期评估疗效、筛选治疗优势人群、将毒性降至最小等。只有阐明这些问题，才能充分发挥其优势，将抗血管生成治疗提升至更高水平。
|
| 关 键 词： | 抗血管生成治疗 耐药 疗效预测 治疗优势人群 |
| 收稿时间： | 2020-08-20 |
Bevacizumab plus irinotecan,fluorouracil, and leucovorin for metastatic colorectal cancer |
| |
| Li Kai. Antiangiogenic therapy: bottlenecks, countermeasures, and future directions[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 47(22): 1140-1144. DOI: 10.3969/j.issn.1000-8179.2020.22.047 |
| |
| Authors: | Li Kai |
| |
| Affiliation: | Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China |
| |
| Abstract: | After a development period of approximately 20 years, anti-angiogenic therapy has now become an important therapeutic tool for neoplasms as it has been shown to have efficacy in combination with chemotherapy, radiotherapy, epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy, and even immunotherapy. However, specific effects of antiangiogenic drugs on the tumor microenvironment lead to specific |
| |
| Keywords: | antiangiogenic therapy resistance to drug prediction of efficacy therapeutic optimal population |
|
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
|
